Hypertension in patients with psoriasis and psoriatic arthritis

Abstract

The article presents data on the features of hypertension (HTN) and the risk factors for its development in patients with psoriasis (PsO) and psoriatic arthritis (PsA). PsO and PsA are often accompanied by cardiovascular diseases which are associated with both chronic systemic Th1-Th17-mediated inflammation and metabolic changes in this group of patients. Currently, data show high rates of HTN in PsO, however, the pathophysiological relationship of these pathologies has not been fully determined. HTN development in PsO and PsA is mediated by many factors. Firstly, metabolism disorders including hyperuricemia, hyperglycemia, dyslipidemia can play a role. Moreover, PsO and PsA often cause stress and depression predisposing to smoking, alcohol consumption, hypodynamia, which are modifiable cardiovascular risk factors. Also, the medications for skin lesions and joint inflammation can lead to high blood pressure. In conclusion, there is no reason to avoid the use of certain antihypertensive drugs in PsO and PsA. Cardiovascular pathology significantly affects the quality of life, social adaptation, and the treatment opportunities of PsO and PsA.